Telomir Pharmaceuticals said its investigational small-molecule therapy Telomir-1 (Zn-Telomir) produced statistically significant reductions in both primary tumor growth and metastatic dissemination in preclinical tumor xenograft models of aggressive triple-negative breast cancer (TNBC). In these animal studies, Telomir-1 lowered primary tumor burden and limited the spread of cancer cells beyond the original tumor site in models with limited responsiveness to standard chemotherapy. The compound also showed comparable tumor-growth inhibition when used alone and enhanced activity when combined with the chemotherapy drug paclitaxel, resulting in greater suppression of tumor growth than either agent alone.